

Interim Financial Statements (Un-audited)
For the period July - September 2022



Beximco Pharmaceuticals Limited

Beximco Pharmaceuticals Limited and its Subsidiaries
Financial Statements (Un-audited)
For the Period July - September 2022

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position (Un-audited)
As at September 30, 2022

Taka '000


	Notes	September 30, 2022	June 30, 2022
ASSETS			
Non-Current Assets			
Property, Plant and Equipment- Carrying Value	5	42,010,610	41,760,331
Right-of-use Assets		603,606	618,891
Intangible Assets		4,450,081	4,562,988
Deferred Tax Asset		86,077	88,640
Goodwill	6	674,570	674,570
Other Investments	7	20,017	23,357
		47,844,961	47,728,777
Current Assets			
Inventories	8	11,696,312	10,405,295
Spares & Supplies		775,304	718,797
Accounts Receivable		3,246,821	3,142,817
Loans, Advances and Deposits	9	2,825,743	2,787,040
Advance Income Tax		212,763	196,635
Cash and Cash Equivalents	10	872,653	1,168,674
		19,629,596	18,419,258
TOTAL ASSETS		67,474,557	66,148,035
SHAREHOLDERS' EQUITY AND LIABILITIES			
Equity Attributable to the Owners of the Company			
Issued Share Capital		4,461,121	4,461,121
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,115,804	1,116,896
Unrealized Gain/(Loss)		17,192	20,532
Retained Earnings		29,196,322	27,747,886
		42,044,502	40,600,498
Non-Controlling Interests		4,001,193	4,035,507
TOTAL EQUITY		46,045,695	44,636,005
Non-Current Liabilities			
Long Term Borrowings-Net of Current Maturity	11 A	3,323,153	3,454,189
Liability for Gratuity, Pension and WPPF & Welfare Funds		3,182,182	2,785,072
Deferred Tax Liability		2,609,139	2,536,838
		9,114,474	8,776,099
Current Liabilities and Provisions			
Short Term Borrowings		7,107,014	6,850,550
Long Term Borrowings-Current Maturity	11 B	1,580,800	2,065,962
Creditors and Other Payables		2,540,569	2,465,039
Accrued Expenses		764,268	1,166,882
Dividend Payable / Unclaimed Dividend		87,755	88,049
Income Tax Payable		233,982	99,449
		12,314,388	12,735,931
TOTAL EQUITY AND LIABILITIES		67,474,557	66,148,035




Osman Kaiser Chowdhury
Director



A B Siddiqui Rahman
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer





Mohammad Asad Ullah, FCS
Executive Director & Company Secretary


Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July - September 2022

	Notes	July -September 2022	Taka '000 July -September 2021
Net Revenue		9,787,202	8,469,321
Cost of Goods Sold	12	(5,362,525)	(4,392,976)
Gross Profit		4,424,677	4,076,345
Operating Expenses		(2,312,939)	(1,975,903)
Administrative Expenses	13	(285,550)	(244,996)
Selling, Marketing and Distribution Expenses	14	(2,027,389)	(1,730,907)
Profit from Operations		2,111,738	2,100,442
Other Income	15	179,187	70,521
Finance Cost		(310,973)	(163,626)
Profit Before Contribution to WPPF & Welfare Funds		1,979,952	2,007,337
Contribution to WPPF & Welfare Funds		(98,210)	(96,092)
Profit Before Tax		1,881,742	1,911,245
Income Tax Expenses		(469,029)	(435,699)
Current Tax		(393,848)	(430,798)
Deferred Tax	16	(75,181)	(4,901)
Profit After Tax		1,412,713	1,475,546
Profit/(Loss) Attributable to:			
Owners of the Company		1,447,027	1,465,308
Non-controlling Interest		(34,314)	10,238
		1,412,713	1,475,546
Other Comprehensive Income/(Loss)		(3,340)	8,007
Total Comprehensive Income		1,409,373	1,483,553
Total Comprehensive Income Attributable to:			
Owners of the Company		1,443,687	1,473,315
Non-controlling Interest		(34,314)	10,238
		1,409,373	1,483,553
Earnings Per Share (EPS)		3.24	3.28
Number of Shares	Nos.	446,112,089	446,112,089


Osman Kaiser Chowdhury
 Director


A B Siddiqur Rahman
 Director


Nazmul Hassan
 Managing Director


Mohammad Ali Nawaz
 Chief Financial Officer


Mohammad Asad Ullah, FCS
 Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity (Un-audited)
For the Period July - September 2022

As at September 30, 2022

Taka '000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity	
Balance as on July 01, 2022	4,461,121	5,269,475	1,689,637	294,951	1,116,896	20,532	27,747,886	40,600,498	4,035,507	44,636,005	
Total Comprehensive Income:											
Profit/(Loss) for the Period	-	-	-	-	-	-	1,447,027	1,447,027	(34,314)	1,412,713	
Other Comprehensive Income/(Loss)	-	-	-	-	-	(3,340)	-	(3,340)	-	(3,340)	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(1,409)	-	1,409	-	-	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	317	-	-	317	-	317	
Balance as on September 30, 2022	4,461,121	5,269,475	1,689,637	294,951	1,115,804	17,192	29,196,322	42,044,502	4,001,193	46,045,695	
Net Asset Value (NAV) Per Share								Tk.	94.25		

As at September 30, 2021

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity	
Balance as on July 01, 2021	4,461,121	5,269,475	1,689,637	294,951	1,121,825	13,767	24,179,783	37,030,559	334,307	37,364,866	
Total Comprehensive Income:											
Profit/(Loss) for the Period	-	-	-	-	-	-	1,465,308	1,465,308	10,238	1,475,546	
Other Comprehensive Income/(Loss)	-	-	-	-	-	8,007	-	8,007	-	8,007	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(1,590)	-	1,590	-	-	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	358	-	-	358	-	358	
Balance as on September 30, 2021	4,461,121	5,269,475	1,689,637	294,951	1,120,593	21,774	25,646,681	38,504,232	344,545	38,848,777	
Net Asset Value (NAV) Per Share								Tk.	86.31		

Osman Kaiser Chowdhury
Director

A B Siddiqur Rahman
Director

Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary


Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows (Un-audited)
For the Period July - September 2022

	Notes	July -September 2022	Taka '000 July -September 2021
Cash Flows from Operating Activities :			
Receipts from Customers and Others		9,853,354	8,863,397
Payments to Suppliers and Employees		(8,584,421)	(6,475,987)
Cash Generated from Operations		1,268,933	2,387,410
Interest Paid		(310,322)	(164,459)
Interest Received		1,310	401
Income Tax Paid		(275,443)	(235,142)
Net Cash Generated from Operating Activities	17	684,478	1,988,210
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(682,416)	(819,779)
Intangible Assets		-	(880)
Synovia Acquisition		-	(4,766,636)
Disposal of Property, Plant and Equipment		20	12,251
Disposal of Intangible Assets		52,125	-
Net Cash Used in Investing Activities		(630,271)	(5,575,044)
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		(619,541)	3,770,738
Net Increase/(Decrease) in Short Term Borrowings		256,464	(251,542)
Dividend Paid		(295)	(64,481)
Net Cash (Used in) / from Financing Activities		(363,372)	3,454,715
Increase/(Decrease) in Cash and Cash Equivalents		(309,165)	(132,119)
Cash and Cash Equivalents at Beginning of Period		1,168,674	675,467
Effect of Exchange Rate Changes on Cash and Cash Equivalents		13,144	1,913
Cash and Cash Equivalents at End of Period	10	872,653	545,261
Number of Shares		446,112,089	446,112,089
Net Operating Cash Flows Per Share		1.53	4.46


Osman Kaiser Chowdhury
 Director


A B Siddiquir Rahman
 Director


Nazmul Hassan
 Managing Director


Mohammad Ali Nawaz
 Chief Financial Officer


Mohammad Asad Ullah, FCS
 Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries

Selected Notes to the Financial Statements (Un-audited)

For the Period July - September 2022

1 Reporting Entity

1.1 About the Company

Beximco Pharmaceuticals Limited (Beximco Pharma/BPL/ the Company) is a public limited company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh. Its GDRs are traded in AIM of the London Stock Exchange.

In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited (Nuvista Pharma/NPL)– a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs. In October 2021, BPL acquired majority stake (54.6%) in Sanofi Bangladesh Limited from Sanofi Group represented through May & Baker Limited and Fisons Limited. The company was subsequently renamed as Synovia Pharma PLC (Synovia Pharma/SPP). Bangladesh Government holds 45.4% shares of the company represented through Bangladesh Chemical Industries Corporation (20%) and Ministry of Industries (25.4%). SPP is a non-listed pharmaceutical company based in Bangladesh.

The corporate headquarters of Beximco Pharma is based in Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 The Subsidiaries

Nuvista Pharma Limited (NPL)

Nuvista Pharma, formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. The Company has been operating in Bangladesh since 1964, with a local manufacturing facility at Tongi, Dhaka. In the post-independent Bangladesh, it was incorporated under Bangladesh Companies Act as a private limited company. In 2006 the foreign shareholding was sold out to Bangladeshi management and was renamed as Nuvista Pharma Limited. In 2011, the company through amendments to its memorandum of association converted it into a public limited company. In 2018, Beximco Pharma acquired majority shareholdings in Nuvista Pharma and thus it became the immediate and ultimate parent of the company.

Synovia Pharma PLC (SPP)

Synovia Pharma PLC (formerly Sanofi Bangladesh Limited) had been a part of Sanofi S.A., a global biopharmaceutical company focused on human health. The company has been operating in Bangladesh since 1958 as part of the British chemical company, May & Baker. Following series of mergers, it was renamed as Sanofi Bangladesh Limited in 2013 before being acquired by Beximco Pharma in 2021 and subsequently renamed as Synovia Pharma PLC. SPP's state-of-the-art manufacturing facilities, including a PIC/S certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over c25 acres of land, located at Tongi, Gazipur. SPP has over 900 employees and produces approximately 100 branded generic products predominantly for the local market. The company also imports finished formulation products for distribution and sale in Bangladesh.

Beximco Pharma API Limited (BPAL)

Beximco Pharma API Limited was formed with an intend to set up a facility at API Industrial Park to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and international markets. It is a private limited company with a paid up capital of Taka 20 million divided into 2 million shares of Taka 10 each, fully held by BPL excepting 10 shares. The company is still in the initial phase of establishment.

1.3 Nature of Business

BPL is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable and Large Volume Intravenous Fluids. Besides formulation products, BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

NPL produces various pharmaceutical products including oral contraceptives, hormone, steroid, anti-histamine, anti-fibrinolytic, anti infective, gastrointestinal, musculoskeletal, respiratory, vitamin & mineral supplement and women's health products which are sold predominantly in the domestic market.

SPP produces generic pharmaceutical products and has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. SPP also imports certain global brands of Sanofi including vaccines, insulins and chemotherapy drugs for sale in Bangladesh market.

NPL and SPP also provide contract manufacturing services.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2022 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. All financial information presented has been rounded off to the nearest thousand Taka except where indicated otherwise.

3. Comparative Information

The Company acquired majority stake in Synovia Pharma PLC (formerly Sanofi Bangladesh Limited) with effect from October 1, 2021. Therefore the comparative prior period unaudited figures (July 2021-September 2021) as reported in the Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Statement of Cash Flows do not include financials of Synovia Pharma PLC.

4. Significant Accounting Policies

4.1 Basis of Consolidation

The financial statements of the subsidiaries-Nuvista Pharma Limited, Synovia Pharma PLC and Beximco Pharma API Limited, have been consolidated with those of Beximco Pharmaceuticals Limited in accordance with IFRS 10: Consolidated Financial Statements.

The Company acquired 85.22% shares of the issued and paid up capital of Nuvista Pharma Limited. This ownership interest is adequate enough to establish control over NPL and thus BPL meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider NPL as a subsidiary.

The Company acquired 54.6% shares of the issued and paid up capital of Synovia Pharma PLC. This ownership interest is adequate enough to establish control over SPP and thus BPL meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider SPP as a subsidiary.

Beximco Pharma API Limited (BPAL) was formed with a paid up capital of Tk.20,000,000 divided into 2,000,000 shares of Tk.10 each, all of which excepting 10 shares are held by Beximco Pharmaceuticals Ltd (BPL). Beximco Pharma API Ltd thus meets the conditions stated in IFRS 10: Consolidated Financial Statements to consider it as a subsidiary.

4.2 Inter-Company Transactions

Assets, Liabilities, Equity, Income, Expenses and Cash Flows arising out of transactions between the Company and the subsidiaries have been eliminated in full in the Consolidated Financial Statements.

4.3. Non-Controlling Interests (NCIs)

Non-Controlling Interests (NCIs) at the date of acquisition has been measured at fair value of the net assets of the acquired company in proportion to the shares of the entitled holders. Profit or Loss and Other Comprehensive Income subsequent to the acquisition has been allocated to the Owners of the Company and to the NCIs.

4.4. Valuation of Goodwill

Goodwill has been determined in accordance with IFRS 3: Business Combination. This represents the excess of the aggregate of Purchase Consideration and the acquisition-date fair value of NCI's share in the net assets over the acquisition-date fair value of the net assets of the subsidiary.

4.5 Investment in Associates

Investment in Associates has been accounted for using the Equity method as per IAS 28: Investment in Associates and Joint Ventures.

	As at September 30, 2022	Taka '000 As at June 30, 2022
5. Property, Plant & Equipment - Carrying Value		
Land	7,579,725	7,468,877
Building and Other Constructions	16,536,182	16,536,450
Plant and Machinery	28,613,860	28,647,335
Furniture and Fixtures	653,475	666,141
Transport and Vehicle	932,032	932,927
Office Equipment	988,245	1,080,834
	55,303,519	55,332,564
Less :Accumulated Depreciation	(14,679,167)	(14,406,915)
Net Book Value	40,624,352	40,925,649
Capital Work in Progress	1,386,258	834,682
Carrying Value	42,010,610	41,760,331
6. Goodwill		
Nuvista Pharma Limited	546,691	546,691
Synovia Pharma PLC.	127,879	127,879
	674,570	674,570
7. Other Investments		
Bangladesh Export Import Co. Ltd.	18,448	21,788
Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
	20,017	23,357
8. Inventories		
Finished Goods	2,563,774	2,486,293
Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit)	9,045,135	7,836,950
Physician Sample	87,403	82,052
	11,696,312	10,405,295
9. Loans, Advances and Deposits		
Clearing & Forwarding	238,213	259,314
VAT	566,371	619,340
Security Deposit and Earnest Money	193,542	158,899
Lease Deposit	2,133	2,133
Advance for Expenses including Capital Expenditure	563,111	654,536
Bank Guarantee Margin	20,894	18,827
Salary Advance/Loan	100,976	93,893
Vehicle Advance	223,487	225,976
Raw & Packing Material	438,853	449,393
Overseas Liaison Office	68,089	67,005
Others	410,074	237,724
	2,825,743	2,787,040

	As at September 30, 2022	Taka '000 As at June 30, 2022
10. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	435,140	279,615
(b) Cash at Bank:		
Current and FC Account	315,167	736,689
FDR & SND Account	122,346	152,370
	872,653	1,168,674
11. Long Term Borrowings		
A. Net of Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	710,011	670,863
Term Loan- Agrani Bank	2,146,805	2,313,749
Term Loan- Dhaka Bank	11,108	12,815
Lease Liability	455,229	456,762
	3,323,153	3,454,189
B. Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	473,341	938,924
Term Loan- Agrani Bank	960,000	960,000
Term Loan- Dhaka Bank	6,609	6,459
Lease Liability	140,850	160,579
	1,580,800	2,065,962
	For the Period July - September 2022	For the Period July - September 2021
12. Cost of Goods Sold		
Work-in-Process (Opening)	684,808	340,573
Materials Consumed	4,106,787	3,695,019
Factory Overhead Consumed	1,404,954	977,720
Total Manufacturing Cost	6,196,549	5,013,312
Work-in-Process (Closing)	(919,652)	(443,329)
Cost of Goods Manufactured	5,276,897	4,569,983
Finished Goods (Opening)	2,486,293	1,299,682
Purchase (Imported and processed)	258,434	-
Finished Goods available	8,021,624	5,869,665
Cost of Sample (transferred to Sample Stock)	(95,325)	(95,097)
Finished Goods (Closing)	(2,563,774)	(1,381,592)
	5,362,525	4,392,976

	For the Period July - September 2022	For the Period July - September 2021
13. Administrative Expenses		
Salary & Allowances	165,074	127,273
Repairs & Maintenance	13,566	17,372
Travelling & Conveyance	6,736	6,648
Company Secretarial, Regulatory Fee and AGM Expense	9,006	8,812
Depreciation	18,312	8,496
Security Expenses	5,383	4,114
Business Acquisition Cost	-	6,672
Other Expenses	67,473	65,609
	<u>285,550</u>	<u>244,996</u>
14. Selling, Marketing and Distribution Expenses		
Salary & Allowances	804,892	630,644
Travelling & Conveyance	203,945	171,347
Market Research & New Products	11,553	18,791
Sample Expenses	116,471	123,300
Literature and News Letter	73,656	71,082
Events, Programs & Campaigns	111,788	69,238
Brand Development	20,734	18,906
Sales Promotion Expenses	53,267	42,082
Distribution Commission	153,708	131,705
Delivery Expense	106,070	96,950
Depreciation and Amortization	78,560	40,976
Export Insurance, Freight and C & F Expenses	50,085	50,275
Security Expenses	5,043	5,171
Bad Debts	675	725
Other Expenses	236,942	259,715
	<u>2,027,389</u>	<u>1,730,907</u>
15. Other Income		
Interest Income	1,310	401
Cash Incentive on Export	63,816	60,494
Royalty	26,203	8,701
Exchange Rate Fluctuation Gain/(loss)	69,396	(1,995)
Profit/(Loss) on Sale of Fixed Assets	(2,079)	2,523
Miscellaneous Income	20,541	397
	<u>179,187</u>	<u>70,521</u>

16. Deferred Tax	For the Period July - September 2022	For the Period July - September 2021
Deferred Tax Expense is arrived at as follows :		
i. Beximco Pharma		
Property, Plant & Equipment (Difference in book value & Tax base)	12,511,720	9,506,995
Deferred liability (Gratuity)	(1,372,926)	(1,152,340)
Provision for Bad Debts	(11,323)	(8,894)
Temporary Difference	11,127,471	8,345,761
Tax Rate	22.5%	22.5%
Deferred Tax Liability at end of the period	2,503,681	1,877,796
Deferred Tax Liability at beginning of the period	2,427,209	1,871,974
Change in Deferred Tax Liability	76,472	5,822
Deferred tax on Revaluation Surplus	317	358
Deferred Tax charged to profit or Loss and Other Comprehensive Income	76,789	6,180
ii. Nuvista Pharma		
Property, Plant & Equipment (Difference in book value & Tax base)	441,327	443,615
Deferred liability (Gratuity)	(182,833)	(149,514)
Provision for Bad Debts	(2,461)	(1,885)
Temporary Difference	256,033	292,216
Tax rate	30%	30%
Deferred Tax Liability	76,810	87,665
Deferred tax on revaluation surplus	28,648	28,648
Deferred tax liabilities at end of the period	105,458	116,313
Deferred tax liabilities at beginning of the period	109,629	117,592
Deferred Tax charged to profit or Loss and Other Comprehensive Income	(4,171)	(1,279)
iii. Synovia Pharma		
Property, Plant & Equipment (Difference in book value & Tax base)	207,094	-
Deferred Liability (Gratuity & Pension)	(116,298)	-
Provision for Bad Debts & Allowance for Inventory	(93,766)	-
Carried forward loss	(310,039)	-
Temporary difference	(313,009)	-
Tax rate	27.50%	-
Deferred Tax Liability/(Asset) at end of the period	(86,077)	-
Deferred Tax Liability/(Asset) at beginning of the period	(88,640)	-
Deferred tax charged to profit or loss and other comprehensive income	2,563	-
	75,181	4,901

For the Period
July - September
2022

For the Period
July - September
2021

17. Reconciliation of Net Profit with Cash Flows from Operating Activities

Profit After Tax	1,412,713	1,475,546
Adjustment to reconcile net profit to Net Cash Generated from Operating Activities :		
Non-cash / Non-operating items:	599,693	282,853
Depreciation	472,069	254,053
Amortization	60,164	24,705
Deferred Tax	75,181	4,901
Exchange Rate Fluctuation Gain on Foreign Currency Bank Loan	3,344	3,656
Gain /(Loss) on Sale of Fixed Assets	2,079	(2,549)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(13,144)	(1,913)
Changes in Working Capital	(1,327,928)	229,811
Inventories	(1,291,017)	(601,222)
Spares & Supplies	(56,507)	(41,118)
Accounts Receivable	(104,003)	324,762
Loans, Advances & Deposits	(71,189)	(26,327)
Gratuity & WPPF	397,110	296,557
Advance Income Tax	(16,128)	-
Creditors and Other Payables	75,530	262,048
Accrued Expenses	(396,257)	(180,545)
Income Tax Payable	134,533	195,656
Net Cash Generated from Operating Activities	684,478	1,988,210

18. Related Party Transaction

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at period end
I & I Services Limited	Local Delivery	8,891,882	1,175,345
	Distribution Commission	153,708	

19. Events after the Reporting Period

- 19.a.** The Board of Directors of the Company recommended 35% cash dividend (i.e. Tk. 3.50 per share) for the year 2021-22. The dividend proposal is subject to shareholders' approval at the forthcoming Annual General Meeting.
- 19.b.** Board of Directors of Nuvista Pharma Limited (NPL) has declared cash dividend @ 40%, i.e. Tk. 4.00 per share for the year 2021-22. The proposed dividend is subject to approval of the shareholders of NPL in the forthcoming Annual General Meeting.
- 19.c.** Dividend declared by the companies has not been accounted for in this interim financial statements.

20. Significant Deviations/Events


- 20.a** The Company acquired majority stake in Synovia Pharma PLC (formerly Sanofi Bangladesh Limited) with effect from October 1, 2021. Therefore the comparative prior period unaudited figures (July - September 2021) as reported in the Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Statement of Cash Flows do not include financials of Synovia Pharma PLC.
- 20.b** Consolidated Earnings Per Share (EPS) for the period July-September 2022 has declined due to decreased EPS of the subsidiary Nuvista Pharma and loss incurred by the other newly acquired subsidiary Synovia Pharma.
- 20.c** Operating Cash Flow per share declined as against comparable prior period due to increased working capital investment consequent to the record devaluation of Taka, increased price of materials and higher domestic inflation. Moreover, the Company needed to maintain additional inventory to protect against any supply chain disruption and to support the organic business growth.




Osman Kaiser Chowdhury
Director



A B Siddiqui Rahman
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Financial Statements (Un-audited)
For the Period July - September 2022

Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at September 30, 2022

Taka '000


	Notes	September 30, 2022	June 30, 2022
ASSETS			
Non-Current Assets			
Property, Plant and Equipment- Carrying Value	3	36,046,309	35,879,081
Right-of-use Assets		551,636	565,077
Intangible Assets		682,391	752,955
Investment in Subsidiaries	4a	6,911,822	6,911,822
Investment In Associates		29,326	29,326
Other Investments	4b	20,017	23,357
Current Assets			
Inventories	5	9,996,886	8,802,040
Spares & Supplies		725,282	664,710
Accounts Receivable		3,037,376	2,739,772
Loans, Advances and Deposits	6	2,538,811	2,510,263
Cash and Cash Equivalents	7	680,969	816,224
TOTAL ASSETS		61,220,825	59,694,627
EQUITY AND LIABILITIES			
Shareholders' Equity			
Issued Share Capital		4,461,121	4,461,121
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,115,804	1,116,896
Unrealized Gain/(Loss)		17,192	20,532
Retained Earnings		28,916,649	27,463,126
Non-Current Liabilities			
Long Term Borrowings-Net of Current Maturity	8 A	3,270,231	3,401,537
Liability for Gratuity and WPPF & Welfare Funds		2,847,266	2,482,847
Deferred Tax Liability	14	2,503,681	2,427,209
Current Liabilities and Provisions			
Short Term Borrowings		6,595,073	6,363,686
Long Term Borrowings-Current Maturity	8 B	1,557,443	2,039,694
Creditors and Other Payables		1,995,567	1,908,465
Accrued Expenses		401,562	576,414
Dividend Payable / Unclaimed Dividend	9	87,076	87,371
Income Tax Payable		198,097	91,666
TOTAL EQUITY AND LIABILITIES		61,220,825	59,694,627




Osman Kaiser Chowdhury
Director



A B Siddiqui Rahman
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July - September 2022

		July -September 2022	July -September 2021
	Notes		Taka '000
Net Sales Revenue		8,258,687	7,805,100
Cost of Goods Sold	10	(4,493,910)	(4,080,850)
Gross Profit		3,764,777	3,724,250
Operating Expenses		(1,751,516)	(1,780,350)
Administrative Expenses	11	(205,216)	(217,865)
Selling, Marketing and Distribution Expenses	12	(1,546,300)	(1,562,485)
Profit from Operations		2,013,261	1,943,900
Other Income	13	253,142	115,589
Finance Cost		(305,110)	(162,869)
Profit Before Contribution to WPPF & Welfare Funds		1,961,293	1,896,620
Contribution to WPPF & Welfare Funds		(93,395)	(90,315)
Profit Before Tax		1,867,898	1,806,305
Income Tax Expenses		(415,784)	(399,991)
Current Tax		(338,995)	(393,811)
Deferred Tax	14	(76,789)	(6,180)
Profit after Tax		1,452,114	1,406,314
Other Comprehensive Income/(Loss)		(3,340)	8,007
Total Comprehensive Income		1,448,774	1,414,321
Earnings Per Share (EPS)		3.26	3.15
Number of Shares		446,112,089	446,112,089

 Osman Kaiser Chowdhury Director	 A B Siddiquir Rahman Director	 Nazmul Hassan Managing Director	 Mohammad Ali Nawaz Chief Financial Officer	 Mohammad Asad Ullah, FCS Executive Director & Company Secretary
--	--	--	--	--

Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the Period July - September 2022

As at September 30, 2022

Taka' 000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total	
Balance as on July 01, 2022	4,461,121	5,269,475	1,689,637	294,951	1,116,896	20,532	27,463,126	40,315,738	
Total Comprehensive Income									
Profit for the Period	-	-	-	-	-	-	1,452,114	1,452,114	
Other Comprehensive Income/(Loss)	-	-	-	-	-	(3,340)	-	(3,340)	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(1,409)	-	1,409	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	317	-	-	317	
Balance as on September 30, 2022	4,461,121	5,269,475	1,689,637	294,951	1,115,804	17,192	28,916,649	41,764,829	
Number of Shares								446,112,089	
Net Asset Value (NAV) Per Share								Tk.	93.62

As at September 30, 2021

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total	
Balance as on July 01, 2021	4,461,121	5,269,475	1,689,637	294,951	1,121,825	13,767	23,856,816	36,707,592	
Total Comprehensive Income									
Profit for the Period	-	-	-	-	-	-	1,406,314	1,406,314	
Other Comprehensive Income/(Loss)	-	-	-	-	-	8,007	-	8,007	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(1,590)	-	1,590	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	358	-	-	358	
Balance as on September 30, 2021	4,461,121	5,269,475	1,689,637	294,951	1,120,593	21,774	25,264,720	38,122,271	
Number of Shares								446,112,089	
Net Asset Value (NAV) Per Share								Tk.	85.45

Osman Kaiser Chowdhury
Director

A B Siddiqur Rahman
Director

Nazmul Hassan
Managing Director

Mohammad Ali Nawaz
Chief Financial Officer

Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the Period July - September 2022

Taka '000


	Notes	July - September 2022	July - September 2021
Cash Flows from Operating Activities :			
Receipts from Customers and Others		8,204,561	8,208,174
Payments to Suppliers and Employees		(6,943,482)	(5,997,509)
Cash Generated from Operations		1,261,079	2,210,665
Interest Paid		(305,110)	(162,869)
Interest Received		-	401
Income Tax Paid		(232,564)	(216,702)
Net Cash Generated from Operating Activities	15	723,405	1,831,495
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(537,984)	(815,499)
Intangible Assets		-	(880)
Synovia Acquisition		-	(4,766,636)
Disposal of Property, Plant and Equipment		-	12,215
Disposal of Intangible Assets		52,125	-
Net Cash Used in Investing Activities		(485,859)	(5,570,800)
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		(616,901)	3,770,738
Net Increase/(Decrease) in Short Term Borrowings		231,387	(150,449)
Dividend Paid	9	(295)	(64,481)
Net Cash (Used in) / from Financing Activities		(385,809)	3,555,808
Increase/(Decrease) in Cash and Cash Equivalents		(148,263)	(183,497)
Cash and Cash Equivalents at Beginning of Period		816,224	647,905
Effect of Exchange Rate Changes on Cash and Cash Equivalents		13,008	1,913
Cash and Cash Equivalents at End of Period	7	680,969	466,321
Number of Shares		446,112,089	446,112,089
Net Operating Cash Flows Per Share		1.62	4.11




Osman Kaiser Chowdhury
Director



A B Siddiqur Rahman
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-audited)
For the Period July - September 2022

1. Reporting Entity

1.1 About the Company

Beximco Pharmaceuticals Limited (Beximco Pharma / BPL/ the Company) is a public limited company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited (Nuvista Pharma/NPL) – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs. In October 2021, BPL acquired majority stake (54.6%) in Sanofi Bangladesh Limited from Sanofi Group represented through May & Baker Limited and Fisons Limited. The company was subsequently renamed as Synovia Pharma PLC (Synovia Pharma/SPP). Bangladesh Government holds 45.4% shares of the company represented through Bangladesh Chemical Industries Corporation (20%) and Ministry of Industries (25.4%). SPP is a non-listed pharmaceutical company based in Bangladesh. Shares of Beximco Pharma are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs are traded in AIM of the London Stock Exchange.

The corporate headquarters of Beximco Pharma is based in Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 Nature of Business

The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable and Large Volume Intravenous Fluids. BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2022 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. All financial information presented has been rounded off to the nearest thousand Taka except where indicated otherwise.

	As at September 30, 2022	Taka '000 As at June 30, 2022
3. Property, Plant & Equipment - Carrying Value		
Land	3,343,741	3,343,741
Building and Other Constructions	15,170,176	15,170,176
Plant and Machinery	26,059,095	26,056,752
Furniture and Fixtures	488,155	483,024
Transport and Vehicle	776,181	776,181
Office Equipment	759,053	758,556
	46,596,401	46,588,430
Less : Accumulated Depreciation	(11,880,445)	(11,490,778)
Net Book Value	34,715,956	35,097,652
Capital Work in Progress	1,330,353	781,429
Carrying Value	36,046,309	35,879,081
4a. Investment in Subsidiaries		
It consists of:		
Nuvista Pharma Limited	2,125,186	2,125,186
Synovia Pharma PLC.	4,766,636	4,766,636
Beximco Pharma API Limited	20,000	20,000
	6,911,822	6,911,822
4b. Other Investment		
Bangladesh Export Import Co. Ltd.	18,448	21,788
Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
	20,017	23,357
5. Inventories		
Finished Goods	1,794,898	1,754,268
Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R&D Materials and Material in Transit)	8,114,585	6,965,720
Physician Sample	87,403	82,052
	9,996,886	8,802,040
6. Loans, Advances and Deposits		
Clearing & Forwarding	238,213	259,314
VAT	545,450	563,668
Security Deposit and Earnest Money	117,254	105,873
Lease Deposit	2,133	2,133
Advance for Expenses including Capital Expenditure	508,482	611,453
Bank Guarantee Margin	20,894	18,827
Advance against Salary	98,726	91,221
Vehicle Advance	153,193	154,557
Raw & Packing Material	438,853	439,515
Overseas Liaison Office	68,089	67,005
Others	347,524	196,697
	2,538,811	2,510,263

	As at September 30, 2022	Taka '000 As at June 30, 2022
7. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	434,947	279,393
(b) Cash at Bank:		
Current and FC Account	246,022	536,831
	<u>680,969</u>	<u>816,224</u>

8. Long Term Borrowings

A. Net of Current Maturity

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	710,011	670,863
Term Loan-Agrani Bank	2,146,805	2,313,749
Leases Liability	413,415	416,925
	<u>3,270,231</u>	<u>3,401,537</u>

B. Current Maturity

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	473,341	938,924
Term Loan-Agrani Bank	960,000	960,000
Leases Liability	124,102	140,770
	<u>1,557,443</u>	<u>2,039,694</u>

i. Unrealised exchange loss on outstanding foreign currency project loan amounting to Tk. 3,344K has been arrived at using the exchange rate prevailing on the date of Statement of Financial Position.

9. Dividend Payable / Unclaimed Dividend

The Dividend Payable/Unclaimed dividend as on September 30, 2022 includes Tk. 44,812K relating to year 2020-21 which has been paid but not yet claimed. The remaining balance relates to dividend for prior years unclaimed to date.

	For the Period July - September 2022	For the Period July - September 2021
10. Cost of Goods Sold		
Work-in-Process (Opening)	610,860	282,756
Materials Consumed	3,714,166	3,515,818
Factory Overhead Consumed	1,079,785	845,138
Total Manufacturing Cost	5,404,811	4,643,712
Work-in-Process (Closing)	(777,838)	(381,118)
Cost of Goods Manufactured	4,626,973	4,262,594
Finished Goods (Opening)	1,754,268	1,188,527
Finished Goods available	6,381,241	5,451,121
Cost of Sample (transferred to Sample Stock)	(92,433)	(93,154)
Finished Goods (Closing)	(1,794,898)	(1,277,117)
	<u>4,493,910</u>	<u>4,080,850</u>

	For the Period July - September 2022	For the Period July - September 2021
11. Administrative Expenses		
Salary & Allowances	114,167	108,897
Repairs & Maintenance	12,019	16,342
Travelling & Conveyance	5,778	6,591
Company Secretarial, Regulatory Fee and AGM Expense	8,836	8,693
Depreciation	10,754	8,039
Security Expenses	4,319	4,114
Business Acquisition Cost	-	6,672
Other Expenses	49,343	58,517
	205,216	217,865
12. Selling, Marketing and Distribution Expenses		
Salary & Allowances	589,280	555,648
Travelling & Conveyance	154,514	146,132
Market Research & New Products	10,650	18,791
Sample Expenses	111,339	120,483
Literature and News Letter	61,622	59,784
Events, Programs & Campaign	72,813	66,378
Brand Development	18,027	16,654
Sales Promotion Expenses	40,006	37,238
Distribution Commission	153,708	131,705
Delivery Expense	106,070	96,950
Depreciation and Amortization	33,614	30,563
Export Insurance, Freight and C & F Expenses	50,025	50,275
Security Expenses	5,043	5,171
Bad Debts	675	725
Other Expenses	138,914	225,988
	1,546,300	1,562,485
13. Other Income		
Interest Income	-	401
Distribution Commission	82,876	36,774
Cash Incentive on Export	63,816	60,494
Royalty	37,191	17,392
Exchange Rate Fluctuation Gain/(loss)	69,259	(1,995)
Sale of Product Dossier	-	2,523
	253,142	115,589
14. Deferred Tax		
Deferred Tax is arrived at as follows :		
Property, Plant & Equipment -Difference in book value & Tax base	12,511,720	9,506,995
Deferred Liability (Gratuity)	(1,372,926)	(1,152,340)
Allowance for Bad Debts	(11,323)	(8,894)
Temporary Difference	11,127,471	8,345,761
Tax Rate	22.5%	22.5%
Deferred Tax Liability at end of the period	2,503,681	1,877,796
Deferred Tax Liability at beginning of the period	2,427,209	1,871,974
Change in Deferred Tax Liability	76,472	5,822
Deferred Tax on Revaluation Surplus	317	358
Deferred Tax	76,789	6,180

**For the Period
July - September
2022**

**For the Period
July - September
2021**

15. Reconciliation of Net Profit with Cash Flows from Operating Activities

Profit after Tax	1,452,114	1,406,314
Adjustment to reconcile net profit to Net Cash Generated from Operating Activities :		
Non-cash / Non-operating Items:	499,723	251,857
Depreciation	414,158	229,674
Amortization	18,440	16,783
Deferred Tax	76,789	6,180
Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan	3,344	3,656
Loss /(Gain) on Sale of Fixed Assets	-	(2,523)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(13,008)	(1,913)
Changes in Working Capital	(1,228,432)	173,324
Inventories	(1,194,846)	(551,968)
Spares & Supplies	(60,572)	(43,038)
Accounts Receivable	(297,604)	288,666
Loans, Advances & Deposits	(61,034)	(24,321)
Gratuity & WPPF	364,419	264,729
Creditors and Other Payables	89,626	164,085
Accrued Expenses	(174,852)	(101,939)
Income Tax Payable	106,431	177,109
Net Cash Generated from Operating Activities	<u>723,405</u>	<u>1,831,495</u>

16. Related Party Transactions

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at period end	Balance Type
a. I & I Services Limited	Local Delivery Distribution Commission	8,891,882 153,708	1,175,345	Dr.
b. Nuvista Pharma Limited	Toll Manufacturing Short Term Loan Advance Office Rent Interest Cost of Services Royalty Distribution Commission	9,170 200,000 2,424 1,333 17,653 10,988 40,030	177,483	Cr.
c. Synovia Pharma PLC.	Toll Manufacturing Cost of Goods/Services Distribution Commission	71,899 68,700 42,846	27,824	Dr.
d. Beximco Pharma API Limited	Short Term Advance	-	730	Dr.

17. Events after the Reporting Period

17.a. The Board of Directors of the Company recommended 35% cash dividend (i.e. Tk. 3.50 per share) for the year 2021-22. The dividend proposal is subject to shareholders' approval at the forthcoming Annual General Meeting.

17.b. Board of Directors of Nuvista Pharma Limited (NPL) has declared cash dividend @ 40%, i.e. Tk. 4.00 per share for the year 2021-22. The proposed dividend is subject to approval of the shareholders of NPL in the forthcoming Annual General Meeting.

17.c. Dividend declared by the companies has not been accounted for in this interim financial statements.




Osman Kaiser Chowdhury
Director



A B Siddiqui Rahman
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary